Research progress of hypoglycemic agents on circulating PCSK9 concentration
10.3760/cma.j.cn101721-20240717-00223
- VernacularTitle:降糖药对循环PCSK9水平影响的研究进展
- Author:
Weijie FAN
1
;
Shanghai LI
1
;
Ruina HUANG
1
;
Xinbin ZHANG
1
;
Wantai WU
1
;
Weijun LIANG
1
Author Information
1. 广东医科大学附属医院心内科，湛江 524000
- Publication Type:Journal Article
- Keywords:
Proprotein convertase subtilisin/kexin type 9;
Diabetes;
Antidiabetic drug;
Low-density lipoprotein cholesterol
- From:
Clinical Medicine of China
2025;41(1):71-75
- CountryChina
- Language:Chinese
-
Abstract:
Long-term glucose metabolism disorders in patient with diabetes is often accompanied by dyslipidemia, especially the elevated level of low-density lipoprotein cholesterol (LDL-C). It is an important risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). Recent studies at home and abroad have also found that diabetes can lead to increased levels of proprotein convertase subtilisin/kexintype 9 (PCSK9). In view of the profound influence of PCSK9 overexpression on low density lipoprotein cholesterol level, cardiovascular risk and atherosclerosis, it is of great significance to explore whether hypoglycemic drugs can reduce the level of PCSK9 in the treatment of diabetes. We summarized the results of the study on the effects of various hypoglycemic drugs on circulating PCSK9 concentration in order to provide ideas for the optimal treatment of diabetes.
